Hyperhidrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hyperhidrosis Market Outlook

Thelansis’s “Hyperhidrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperhidrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hyperhidrosis Overview

Hyperhidrosis, a condition marked by excessive sweating, arises from the overstimulation of cholinergic receptors on eccrine glands. This disorder stands out by causing sweat production beyond what is necessary for maintaining a stable body temperature. Eccrine glands are most concentrated in axillae, palms, soles, and faces, making these regions the primary sites linked with hyperhidrosis. The malfunctioning of the acetylcholine negative feedback loop in these individuals is likely responsible for the shift from a normal physiological response to an abnormal pathological one. It is categorized into primary and secondary forms, each demanding distinct approaches to management and treatment. The primary variant typically emerges earlier in life and is characterized by more localized symptoms. On the other hand, the secondary type usually arises due to medication side effects or systemic conditions, particularly those involving the nervous system. Classification of hyperhidrosis into primary or secondary is crucial because the treatment strategies significantly differ between these two groups. Despite various literature reviews, the exact cause of primary hyperhidrosis remains unknown. Genetic factors are thought to contribute to excessive neural stimulation, although the mechanism is not fully comprehended. Identifying secondary causes is generally easier, as they are associated with medications like dopamine agonists, selective serotonin reuptake inhibitors (SSRIs), antipsychotics, and insulin, as well as systemic disorders including diabetes mellitus, hyperthyroidism, Parkinson's disease, and other neurological conditions, and even tumors like pheochromocytoma and lymphoma. It can be prompted by almost any febrile illness, chronic alcohol misuse, and tuberculosis. The development of segmental or localized hyperhidrosis is uncommon but can occur in areas like the forehead, axilla, palms, feet, or forearms in certain adults. Postmenopausal women might also experience moderate to severe hyperhidrosis around their face and scalp. Eccrine sweat glands receive sympathetic innervation through cholinergic fibers, which trigger impulses in response to the body's temperature control needs during physical or psychological stress. The hypothalamus's thermoregulatory center influences the sweat glands through sympathetic innervation. The activation of muscarinic receptors by cholinergic stimulation induces sweating. In cases of hyperhidrosis, the sympathetic nervous system becomes hyperactive, leading to excessive acetylcholine release from nerve endings. It is hypothesized that the negative feedback mechanism to the hypothalamus might be compromised, causing the body to sweat excessively for cooling. This pathological response can be prompted by medications that enhance acetylcholine release or systemic medical conditions that heighten sympathetic responses. Various topical and systemic agents are available for treating hyperhidrosis. Initial treatment usually involves using over-the-counter aluminum chloride hexahydrate at 20% concentration for 3 to 4 nights and as needed on subsequent nights. A recent addition to the treatment options is topical glycopyrronium tosylate, a premoistened cloth containing a 2.4% glycopyrronium solution. Hyperhidrosis has a guarded prognosis. While it's not life-threatening, it can lead to cosmetic concerns and even work-related difficulties. People with severe hyperhidrosis often experience a diminished quality of life.

• The prevalence of hyperhidrosis is approximately 4.8%, encompassing around 15.3 million individuals in the United States. Among them, 70% report experiencing severe excessive sweating in at least one body area.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: